A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Trial Profile

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Surotomycin (Primary) ; Vancomycin
  • Indications Clostridium infections; Diarrhoea; Intestinal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Cubist Pharmaceuticals; Merck & Co
  • Most Recent Events

    • 06 Sep 2017 Results published in the Journal of Antimicrobial Chemotherapy.
    • 02 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Aug 2015 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top